Searchable abstracts of presentations at key conferences in endocrinology

ea0095p13 | Bone | BSPED2023

Cessation of burosumab treatment in adolescent patients with XLH: A multi-centre case series

Uday Suma , Jarvis Charlotte , Ramakrishnan Renuka , Mushtaq Talat , Williams Angela

Background: X-linked hypophosphataemia (XLH) is a genetic condition that causes significant skeletal deformities and is associated with lifelong disability and pain. In October 2018, the NHS in England recommended burosumab, an anti-FGF23 antibody, for treating XLH with radiographic evidence of bone disease in children aged 1 year and over, and in young people with growing bones. The clinical and cost effectiveness of burosumab for treating adults with XLH is ...

ea0095oc10.1 | Oral Communications 10 | BSPED2023

The real-world experience of long acting growth hormone in children with growth hormone deficiency

Ramya Gokul Pon , Jarvis Charlotte , Laing Peter , Das Urmi , Ramakrishnan Renuka , Dharmaraj Poonam , Blair Jo , Didi Mohammed , Senniappan Senthil

Introduction: Long-acting growth hormone (LaGH) therapy has emerged as a newer treatment option for children, with the potential to improve adherence and compliance. Clinical trials have shown LaGH formulations to be effective and safe in children with GH deficiency (GHD). Somatrogon (Ngenla) is licensed for use in children with GHD over than 3 years of age.Objective: We report the real-world experience of using once wee...

ea0085p45 | Pituitary and Growth 1 | BSPED2022

The use of 6-monthly GnRH analogues in the paediatric population

Apperley Louise , Dharmaraj Poonam , Blair Joanne , Ramakrishnan Renuka , Das Urmi , Didi Mohamed , Laing Peter , Yung Zoe , Cassidy Kelly , Blundell Pauline , Jarvis Charlotte , Parkinson Jennifer , Senniappan Senthil

Background: Pubertal progression is inhibited in central precocious puberty with the use of gonadotropin releasing hormone (GnRH) analogues. They are usually given every 10 to 12 weeks via an intramuscular depot, but more recently, a 6-monthly preparation has become available for clinical use.Aim: The aim of this project was to evaluate the efficacy and acceptability of 6-monthly triptorelin, a GnRH analogue, at a tertiary childrenÂ’s hospital.<p...